News @Gotham

February 14, 2019 - Gotham Therapeutics Strengthens Board of Directors and Scientific Advisory Board

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, today announced the appointment of Carlo Incerti, M.D., Ph.D. as an independent Board Member. In addition, the company today added Thomas Tuschl, Ph.D. as a Scientific Advisor.

 
nyc-muc-2-blurred.jpg
Gotham-Group.jpg

PRESS RELEASE

Gotham Therapeutics Launches with $54 Million Series A

In October 2018, Gotham Therapeutics debuted with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One.

UPCOMING EVENT

ChinaBio® Partnering Forum

Meet the team at the 11th Annual ChinaBio® Partnering Forum at the Kerry Hotel in Shanghai, China, May 08 - 09, 2019.

architecture-3033561_1920.jpg

UPCOMING EVENT

NewYorkBIO/NYSE Emerging Company Showcase

Meet the team at the NewYorkBIO/NYSE Emerging Company Showcase at the New York Stock Exchange, NY, USA, May 13, 2019.

UPCOMING EVENT

8th DDIP

Meet the team at the 8th Drug Discovery Innovation Programme at the Embassy Suites by Hilton Boston at Logan Airport, Boston, MA, USA, May 21 -22, 2019.

45482F55.jpg

UPCOMING EVENT

2nd Symposium on Nucleic Acid Modifications

Meet the team at the 2nd Symposium on Nucleic Acid Modifications “RNA modifications: Form, function and mechanism” at the Weizmann Institute of Science, Rehovot, Israel, June 25-27, 2019.

UPCOMING EVENT

1st RNA Epigenetics in Human Disease Conference

Meet the team at the 1st RNA Epigenetics in Human Disease Conference at the St Catharine’s College, Cambridge, UK, September 17-20, 2019.

 

Stay In Touch! 

Gotham Therapeutics will be at the forefront of epitranscriptomics research and drug discovery. Staying in touch with us means staying up-to-date on the field.

contact.jpg